Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1487516

Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China : A retrospective study

Provisionally accepted
Yao Yao Yao Yao 1Wenjuan Di Wenjuan Di 2Fangkai He Fangkai He 2Bin Liu Bin Liu 3*Xue Chen Xue Chen 4*Xiaojun Guan Xiaojun Guan 5*Zhou Huang Zhou Huang 6*Ying Wang Ying Wang 1*Depei Wu Depei Wu 1*
  • 1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
  • 2 Pulmonary and Critical Care Medicine, Kunshan Hospital of Traditional Chinese Medicine, Suzhou, China
  • 3 Suzhou Hopes Hematonosis Hospital, Suzhou, Jiangsu Province, China
  • 4 Department of Radiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China
  • 5 Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China
  • 6 Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China

The final, formatted version of the article will be published soon.

    Background and aim: Patients diagnosed with cancer, particularly those with hematologic malignancies, frequently exhibit a state of immunosuppression. Currently, there remains a scarcity of dependable biomarkers for assessing the severity of COVID-19 in individuals with hematologic malignancies. We conducted a retrospective study of morbidity and mortality in patients with hematological malignancies (HM) who had contracted COVID-19. The aim was to offer a reference for clinical diagnosis and treatment.: A total of 71 patients with HM-confirmed COVID-19 were enrolled from December 2022 to May 2023. Clinical symptoms, laboratory findings, and treatment approaches were collected and documented. Patients were classified into survival and death groups based on their COVID-19 outcomes, and statistical analysis was 2 performed on the clinical data from both groups.Results: Among the 71 patients, 57 (80.3%) were alive, and 14 (19.7%) had died. The mean age of patients in the death group was significantly higher than that of the survival group (51.29±20.76 vs. 49.47±13.04, P=0.030). The proportion of patients receiving mechanical ventilation was significantly higher in the death group (P<0.001). The mortality rate was significantly higher in the critically severe group compared to the mild, moderate, and severe groups (P<0.001). Correlation analysis revealed that certain laboratory indicators lactic acid dehydrogenase (LDH), albumin (ALB), creatine kinase (CK), troponin T (TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP) and fibrin degradation product (FDP), which exhibited significant differences between groups, were significantly correlated with COVID-19-related mortality (all P<0.05).The Cox proportional hazards model indicated that LDH was an independent risk factor associated with the prognosis of HM-confirmed COVID-19.Patients with hematologic malignancies suffer severe morbidity and mortality due to COVID-19 infection. LDH may serve as a risk factor associated with prognosis in the treatment of COVID-19. Monitoring variations in LDH levels can assist healthcare providers in evaluating disease progression, adjusting treatment plans in a timely manner, and predicting patient outcomes.

    Keywords: hematological malignancy, COVID-19, Mortality, indicator, prognosis

    Received: 28 Aug 2024; Accepted: 19 Nov 2024.

    Copyright: © 2024 Yao, Di, He, Liu, Chen, Guan, Huang, Wang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Bin Liu, Suzhou Hopes Hematonosis Hospital, Suzhou, 215000, Jiangsu Province, China
    Xue Chen, Department of Radiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China
    Xiaojun Guan, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China
    Zhou Huang, Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China
    Ying Wang, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
    Depei Wu, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.